Multi omics approach to unravel the regorafenib resistant mechanism in colorectal cancer and to identify novel anti cancer agents

dc.contributor.guideMagani,Sri Krishna Jayadev
dc.coverage.spatial
dc.creator.researcherRasool,Fayyaz
dc.date.accessioned2025-05-30T09:13:22Z
dc.date.available2025-05-30T09:13:22Z
dc.date.awarded2024
dc.date.completed2024
dc.date.registered2018
dc.description.abstractAcquired Drug resistance significantly contributes to cancer recurrence and fatality. Kinases play a pivotal role in cell survival and proliferation and hence inhibition of the kinases is one of the therapeutic strategies used in cancer therapy. The emergence of resistance development to these inhibitors was reported. The mechanism of acquired drug resistance against these muti kinase inhibitors is still to be explored. In this context our laboratory has developed a resistant cell line model against regorafenib, an approved multi kinase inhibitor for advanced colorectal cancer. A multi omics approach has been employed to understand the mechanism of resistance development. A comparative proteome, Phospho-proteome, exome, and methylome profiling were performed with Drug sensitive HCT116 And Drug resistant HCT116 cells. Elevated levels of PI3K/AKT/mTOR, eIF2, Glucose metabolism, and HIF signalling were recorded from proteome data in our regorafenib-resistant HCT116 cells. Additionally, we identified a large set of genes related to tight junctions, ABC transporters, apoptotic and PI3K/AKT/mTOR pathways to be mutated in resistance HCT116 cells in an exome study. Differential methylation of RNA polymerase, apoptotic, TGF-and#946; and Ras family-related genes are seen in our methylome data. Our findings suggest that the PI3K/AKT/mTOR pathway plays a significant role in the acquisition of resistance in HCT116 cells. A promising approach in cancer treatment involves combining therapies to increase survival rates and fight against drug resistance. We investigated the efficacy of combining regorafenib with Rapamycin and Torin1 (mTOR inhibitors) to counter resistance in colorectal cancer cells. By evaluating cytotoxicity pathways, in vitro toxicity, and mode of cell death induction, we seek to resensitize regorafenib-resistant HCT116 cells, potentially offering new avenues for treating colorectal cancer patients with acquired resistance against kinase inhibitors. Chemotherapy is a common cancer treatment that faces challenges.
dc.description.note
dc.format.accompanyingmaterialDVD
dc.format.dimensions
dc.format.extent
dc.identifier.researcherid
dc.identifier.urihttp://hdl.handle.net/10603/642612
dc.languageEnglish
dc.publisher.institutionDepartment of Life Sciences
dc.publisher.placeGreater Noida
dc.publisher.universityShiv Nadar University
dc.relation
dc.rightsuniversity
dc.source.universityUniversity
dc.subject.keywordBiophysics
dc.subject.keywordLife Sciences
dc.subject.keywordMolecular Biology and Genetics
dc.titleMulti omics approach to unravel the regorafenib resistant mechanism in colorectal cancer and to identify novel anti cancer agents
dc.title.alternative
dc.type.degreePh.D.

Files

Original bundle

Now showing 1 - 5 of 11
Loading...
Thumbnail Image
Name:
01_title page.pdf
Size:
75.17 KB
Format:
Adobe Portable Document Format
Description:
Attached File
Loading...
Thumbnail Image
Name:
02_preliminary pages.pdf
Size:
996.06 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
03_contents.pdf
Size:
155.71 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
04_abstract.pdf
Size:
25.01 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
05_chapter-1.pdf
Size:
1.41 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description: